Neisvac-C

N. meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid A, the active ingredient in Neisvac-C, is a vaccine presented as an injectable solution for intramuscular use. It is employed to prevent invasive disease caused by Neisseria meningitidis serogroup C in individuals at risk, including infants, adolescents and travelers to endemic regions.

GNH USA supplies Neisvac‑C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable cold‑chain logistics and regulatory support for global distribution.

Neisvac‑C is a meningococcal conjugate vaccine that targets Neisseria meningitidis serogroup C to prevent invasive disease. - Infants and young children: provides early protection against serogroup C meningococcal disease. - Adolescents and adults: maintains immunity and reduces risk of infection in later life. - Travelers to endemic areas: lowers the chance of acquiring serogroup C meningococcal infection during travel.

Neisvac‑C may be associated with a range of post‑vaccination reactions, most of which are mild and self‑limiting. Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: low‑grade temperature rise within 24 hours. Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder reported after vaccination. - Severe local reaction: extensive swelling or necrosis at the site.

Before administering Neisvac‑C, healthcare professionals should observe several precautionary measures to ensure safety. - Allergy assessment: avoid use in individuals with known hypersensitivity to any vaccine component. - Pregnancy consideration: consult a qualified healthcare provider before vaccinating pregnant women. - Immunocompromised patients: evaluate benefit‑risk balance as response may be reduced. - Fever monitoring: observe and treat post‑vaccination fever or systemic symptoms as needed. - Concomitant vaccines: follow recommended intervals when co‑administering with other vaccines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neisvac‑C can interact with other medical products, influencing its immunogenicity or safety profile. Major Interactions (Avoid): - Live attenuated vaccines: should not be given simultaneously; separate administration by at least 4 weeks. Moderate Interactions (Monitor Closely): - Immunoglobulin therapy: may diminish vaccine response; schedule at least 4 weeks apart. - Antipyretic prophylaxis: routine use before vaccination may blunt antibody production. - Immunosuppressive drugs: can reduce immunogenicity; monitor antibody levels if possible. - Blood products: transfusions within 48 hours may interfere with vaccine efficacy.